{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:19Z","timestamp":1793146399591,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Yangzte University","award":["201106616"],"award-info":[{"award-number":["201106616"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.bbrc.2016.12.025","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T13:16:32Z","timestamp":1480943792000},"page":"1259-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma"],"prefix":"10.1016","volume":"482","author":[{"given":"Dehua","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2016.12.025_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2016.12.025_bib2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/cncr.20998","article-title":"Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years","volume":"103","author":"Shiboski","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2016.12.025_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000343796","article-title":"Prognostic significance of invasion depth in oral tongue squamous cell carcinoma","volume":"74","author":"Tan","year":"2012","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"10.1016\/j.bbrc.2016.12.025_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.oraloncology.2010.06.006","article-title":"Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I)","volume":"46","author":"Bello","year":"2010","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.oraloncology.2010.06.008","article-title":"Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II)","volume":"46","author":"Bello","year":"2010","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin's antiviral mechanism of action: lethal mutagenesis?","volume":"80","author":"Crotty","year":"2002","journal-title":"J.\u00a0Mol. Med. Berl."},{"key":"10.1016\/j.bbrc.2016.12.025_bib7","doi-asserted-by":"crossref","first-page":"e0136746","DOI":"10.1371\/journal.pone.0136746","article-title":"Ribavirin inhibits the activity of mTOR\/eIF4E, ERK\/Mnk1\/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2016.12.025_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/leu.2011.57","article-title":"Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens","volume":"25","author":"Kraljacic","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2016.12.025_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.163","article-title":"Ribavirin targets eIF4E dependent Akt survival signaling","volume":"375","author":"Tan","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2016.12.025_bib10","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1261\/rna.2238705","article-title":"Further evidence that ribavirin interacts with eIF4E","volume":"11","author":"Kentsis","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.bbrc.2016.12.025_bib11","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0406927102","article-title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","volume":"101","author":"Kentsis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2016.12.025_bib12","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","article-title":"Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors","volume":"67","author":"Larsson","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2016.12.025_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2016.12.025_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","article-title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","volume":"114","author":"Assouline","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2016.12.025_bib15","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","article-title":"Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells","volume":"103","author":"Kharas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2016.12.025_bib16","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/1535-7163.MCT-07-2357","article-title":"eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling","volume":"7","author":"Soni","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2016.12.025_bib17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cellsig.2016.06.005","article-title":"Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy","volume":"28","author":"Grzmil","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.bbrc.2016.12.025_bib18","first-page":"123","article-title":"Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer","volume":"1836","author":"Khan","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2016.12.025_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.oraloncology.2011.12.006","article-title":"Ras oncogenes in oral cancer: the past 20 years","volume":"48","author":"Murugan","year":"2012","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib20","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.4317\/medoral.18772","article-title":"Oral cancer: current role of radiotherapy and chemotherapy","volume":"18","author":"Huang","year":"2013","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"10.1016\/j.bbrc.2016.12.025_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1368-8375(02)00141-0","article-title":"5-Fluorouracil and cisplatin in the treatment of advanced oral cancer","volume":"39","author":"Andreadis","year":"2003","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib22","article-title":"Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network Meta-analysis","author":"Berden","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib23","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1128\/JVI.02349-15","article-title":"Investigating the influence of ribavirin on human respiratory syncytial virus RNA synthesis by using a high-resolution transcriptome sequencing Approach","volume":"90","author":"Aljabr","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.oraloncology.2007.05.003","article-title":"Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature","volume":"44","author":"Martin","year":"2008","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2016.12.025_bib25","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.carres.2009.05.017","article-title":"Synthesis of novel ribavirin hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells","volume":"344","author":"Liu","year":"2009","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.bbrc.2016.12.025_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1475-2867-14-63","article-title":"Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in\u00a0vitro","volume":"14","author":"Teng","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrc.2016.12.025_bib27","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/cncr.21476","article-title":"Akt activation correlates with adverse outcome in tongue cancer","volume":"104","author":"Massarelli","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2016.12.025_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bjc.2011.495","article-title":"Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma","volume":"106","author":"Erlich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2016.12.025_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2016.12.025_bib30","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16320691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16320691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T01:55:13Z","timestamp":1536198913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16320691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0006291X16320691"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.025","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}